RU2602771C2 - Вакцина мбтк против астмы - Google Patents

Вакцина мбтк против астмы Download PDF

Info

Publication number
RU2602771C2
RU2602771C2 RU2014133042/15A RU2014133042A RU2602771C2 RU 2602771 C2 RU2602771 C2 RU 2602771C2 RU 2014133042/15 A RU2014133042/15 A RU 2014133042/15A RU 2014133042 A RU2014133042 A RU 2014133042A RU 2602771 C2 RU2602771 C2 RU 2602771C2
Authority
RU
Russia
Prior art keywords
tool according
agent
liposome
kda
asthma
Prior art date
Application number
RU2014133042/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2014133042A (ru
Inventor
ИГЛЕСИАС Пере Хоан КАРДОНА
РИЕРА Исабель АМАТ
МОРЕНО Бланка РЕЕС
ФАБРЕГАТ Мария Мерсе АМАТ
Original Assignee
Арчивель Фарма, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арчивель Фарма, С.Л. filed Critical Арчивель Фарма, С.Л.
Publication of RU2014133042A publication Critical patent/RU2014133042A/ru
Application granted granted Critical
Publication of RU2602771C2 publication Critical patent/RU2602771C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014133042/15A 2012-01-12 2012-01-12 Вакцина мбтк против астмы RU2602771C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Publications (2)

Publication Number Publication Date
RU2014133042A RU2014133042A (ru) 2016-02-27
RU2602771C2 true RU2602771C2 (ru) 2016-11-20

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014133042/15A RU2602771C2 (ru) 2012-01-12 2012-01-12 Вакцина мбтк против астмы

Country Status (15)

Country Link
US (1) US9682042B2 (enExample)
EP (1) EP2802345B1 (enExample)
CN (1) CN104411326B (enExample)
AU (1) AU2012365465B2 (enExample)
BR (1) BR112014017217B1 (enExample)
CA (1) CA2861074C (enExample)
DK (1) DK2802345T3 (enExample)
ES (1) ES2670493T3 (enExample)
IN (1) IN2014MN01594A (enExample)
NO (1) NO2802345T3 (enExample)
PL (1) PL2802345T3 (enExample)
PT (1) PT2802345T (enExample)
RU (1) RU2602771C2 (enExample)
WO (1) WO2013104943A1 (enExample)
ZA (1) ZA201405107B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (zh) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 一种可变形脂质体的制备方法，及其制备的可变性脂质体
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008053055A1 (es) * 2006-10-30 2008-05-08 Archivel Farma, Sl Vacuna profiláctica contra la tuberculosis
US20090081284A1 (en) * 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
WO2010031883A1 (es) * 2008-09-19 2010-03-25 Archivel Farma, S.L. Agente inmunoterapéutico apropiado para la profilaxis primaria de la tuberculosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9900378A3 (en) 1995-02-22 1999-11-29 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (pt) 2001-07-17 2005-11-08 Univ Minas Gerais Composições imunogênicas contendo microesferas biodegradáveis encapsulando antìgenos, vetores gênicos e adjuvantes
ES2231037B1 (es) 2003-10-31 2005-12-16 Archivel Technologies, Sl Agente inmunoterapico util para el tratamiento combinado de la tuberculosis en asociacion con otros farmacos.
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California PROTEOMICS WITH HIGH THROUGHPUT
PT2426141E (pt) 2005-04-29 2014-11-25 Glaxosmithkline Biolog Sa Método para prevenção ou tratamento de uma infecção por m. tuberculosis
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
CN101969976A (zh) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 针对分枝杆菌的多肽疫苗和接种策略
EP2421557B1 (en) 2009-04-24 2018-12-05 Statens Serum Institut A tuberculosis tb vaccine to prevent reactivation
SG190937A1 (en) 2010-12-14 2013-07-31 Glaxosmithkline Biolog Sa Mycobacterium antigenic composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090081284A1 (en) * 2006-04-20 2009-03-26 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
WO2008053055A1 (es) * 2006-10-30 2008-05-08 Archivel Farma, Sl Vacuna profiláctica contra la tuberculosis
WO2010031883A1 (es) * 2008-09-19 2010-03-25 Archivel Farma, S.L. Agente inmunoterapéutico apropiado para la profilaxis primaria de la tuberculosis
EP2332571A1 (en) * 2008-09-19 2011-06-15 Archivel Farma, S.l. Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Y.RIFFO-VASQUEZ et al. Effect of Mycobacterium tuberculosis chaperonins on bronchial eosinophilia and hyper-responsiveness in a murine model of allergic inflammation // Clin Exp Allergy 2004; 34:712-719;. Yu DENG et al. The Antiasthma Effect of Neonatal BCG Vaccination Does Not Depend on the Th17/Th1 but IL-17/IFN-γ Balance in a BALB/c Mouse Asthma Model.//Journal of Clinical Immunology, June 2011, Volume 31, Issue 3, pp 419-429, First online: 22 February 2011. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2652752C1 (ru) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Способ лечения бронхиальной астмы

Also Published As

Publication number Publication date
CA2861074C (en) 2018-11-06
AU2012365465A1 (en) 2014-08-21
CA2861074A1 (en) 2013-07-18
EP2802345B1 (en) 2018-03-07
DK2802345T3 (en) 2018-04-30
ES2670493T3 (es) 2018-05-30
AU2012365465B2 (en) 2017-05-18
PL2802345T3 (pl) 2018-08-31
NO2802345T3 (enExample) 2018-08-04
CN104411326B (zh) 2018-02-02
US20150132364A1 (en) 2015-05-14
PT2802345T (pt) 2018-04-24
EP2802345A1 (en) 2014-11-19
WO2013104943A1 (en) 2013-07-18
ZA201405107B (en) 2020-11-25
RU2014133042A (ru) 2016-02-27
BR112014017217A8 (pt) 2017-07-04
BR112014017217B1 (pt) 2023-01-17
US9682042B2 (en) 2017-06-20
CN104411326A (zh) 2015-03-11
IN2014MN01594A (enExample) 2015-05-08
BR112014017217A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
US9877917B2 (en) Liposome formulation suitable for treating or preventing tuberculosis
US20100272756A1 (en) Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2015150567A1 (en) Novel methods for inducing an immune response
AU2012365465B2 (en) MTB-C vaccine against asthma
CN104736170B (zh) 用于抗细胞内病原体的治疗的包含固体纳米颗粒和至少一种抗原的药物组合物
US20260137766A1 (en) Liposome formulations for treatment of active tuberculosis
EP2332571A1 (en) Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
EP2471511A1 (en) Liposome formulation suitable for treating or preventing tuberculosis
EA053229B1 (ru) Применение липосомных композиций для лечения активной формы туберкулеза
HK1171659A (en) Liposome formulation suitable for treating or preventing tuberculosis